Overactivation of the IDO1 pathway in patients with chronic inflammatory diseases, or in patients treated with type I IFN, was proposed to cause depression via central serotonin depletion or increased production of neurotoxic Quin in the brain (36). Here, IDO1 is linked to depressive symptom measurement.